HHorinouchi· @HHorinouchi · X·· 2 天前评分60
正文 · 原文
🆙#ESMO26 Rapid Oral: #LCSM Non-Mets 🔥iTHYM: Ivonescimab Plus Chemotherapy as First-Line Treatment in Recurrent/Metastatic Thymic Carcinoma: Results From the Phase II Study 🎙️Dr. Xue Hou 🔢4156RO 🎯Met Primary Endpoint: 6-Mo PFS Rate (All 19 Evaluable Pts Progression-Free) 🎯ORR 83.3%, DCR 100% (n=24) ☑️NCT06750952 🔗 https://t.co/a1n3LKUDDS @OncoAlert @Larvol @myESMO @IASLC
热度 4 · 4 赞 · 0 回复 · 0 转发
会议摘要
NCT06750952NCT06750952按 - **标题 / Title：** Ivonescimab Combined with Chemotherapy As First-line Treatment of Relapsed or Metastatic Thymic Cancer: a Prospective, Single Arm, Phase II Trial 对上
- **标题 / Title：** Ivonescimab Combined with Chemotherapy As First-line Treatment of Relapsed or Metastatic Thymic Cancer: a Prospective, Single Arm, Phase II Trial读摘要原文 →来源：HHorinouchi · x.com